Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

NCT ID: NCT05229341

Last Updated: 2025-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-22

Study Completion Date

2026-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To evaluate the effect of Diagnostic DNA Methylation Signatures (DDMS-2) results (positive predictive value \[PPV\], negative predictive value \[NPV\], sensitivity and specificity) on physician decision-making for clinical management of 800 indeterminate thyroid nodules.

SECONDARY OBJECTIVES:

I. To determine sensitivity and specificity, PPV, NPV of DDMS-2 with 1450 needle biopsies including 800 needle biopsies with indeterminate cytopathology.

II. Compare the diagnostic accuracy between DDMS-2 and two currently used diagnostic approaches based on genetic alterations and gene expression within the same prospective cohort of 800 indeterminate needle biopsies.

OUTLINE:

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Gland Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (needle biopsy, DDMS-2)

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

Group Type EXPERIMENTAL

Diagnostic Procedure

Intervention Type PROCEDURE

Analysis via DDMS-2

Electronic Health Record Review

Intervention Type OTHER

Review of medical records

Needle Biopsy

Intervention Type PROCEDURE

Undergo needle biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic Procedure

Analysis via DDMS-2

Intervention Type PROCEDURE

Electronic Health Record Review

Review of medical records

Intervention Type OTHER

Needle Biopsy

Undergo needle biopsy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diagnostic Method Diagnostic Technique Diagnostic Test Aspiration Biopsy Puncture Biopsy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis
* Over the age of 18
* Any gender, race and ethnicity
* Patients must provide informed consent prior to use of their tissues and clinical data

Exclusion Criteria

* Children are excluded from the study, since the biology of children thyroid nodules is different from adults
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

City of Hope Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John H Yim

Role: PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

City of Hope Medical Center

Duarte, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

John H. Yim

Role: primary

626-218-3590

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2021-12556

Identifier Type: REGISTRY

Identifier Source: secondary_id

21129

Identifier Type: OTHER

Identifier Source: secondary_id

P30CA033572

Identifier Type: NIH

Identifier Source: secondary_id

View Link

21129

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thyroid Nodule Gene Sequencing in a Danish Population
NCT05377736 ACTIVE_NOT_RECRUITING NA
Hyperthyroid Follow-Up Study
NCT02989103 COMPLETED
PACE4 in Thyroid Cancer
NCT03160482 COMPLETED